LYFT Inc vs Zimmer Biomet Holdings Inc — how do they compare? LYFT Inc trades at $16.2 (market cap $5.90B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.88B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.9× LYFT Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LYFT | ZBH | |
|---|---|---|
Market Cap | $5.90B | $16.88B |
Volume | 9,741,129 | 1,991,354 |
Sector | Technology | Health |
52-Week High | $24.57 | $103.98 |
52-Week Low | $12.65 | $79.58 |
Typical Hold Time | 47 Days | 89 Days |
Enterprise Value | $5.37B | $23.95B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.60, down 1.02% with a bullish technical signal despite recent earnings misses. The company shows strong fundamental improvement with revenue growing from $4.1B in 2022 to $6.3B in 2025 and achieving profitability with $2.84B net income. Recent developments include European expansion and a $272.5M legal settlement. Valuation metrics appear attractive with P/E of 2.27 and P/S of 0.93, though EV/EBITDA remains elevated at 33.28.
Lyft presents a mixed outlook with strong cash flow growth and expanding operations balanced against competitive pressures and regulatory risks. The stock trades below analyst consensus target of $18.07, offering potential upside, but faces headwinds from driver classification lawsuits and market saturation concerns. Execution on European expansion and sustained profitability will be key catalysts for further appreciation.
Zimmer Biomet (ZBH) trades at $88.91, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.23B in 2025, with net income of $705.1M, and has beaten EPS estimates for the last three quarters. Recent news highlights a quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The outlook is mixed: strong fundamentals and consistent earnings beats support growth, but technical indicators and rising debt-to-asset ratios pose risks. Analyst consensus suggests a 16% upside to the $103.11 price target, though nearly half of analysts recommend Hold. Key risks include competitive pressures and execution of the company's strategic initiatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →